Clincosm LogoSign in Get a demo

durvalumab

Showing 1 - 7 of 7
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)

Recruiting
  • Durvalumab
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jan 3, 2023

Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab Trial in Chongqing, Zhengzhou, Chengdu (Low-dose radiotherapy,

Recruiting
  • Lung Cancer
  • +2 more
  • Low-dose radiotherapy
  • +2 more
  • Chongqing, Chongqing, China
  • +2 more
May 4, 2022

Lung Cancer, Small Cell Lung Cancer, Durvalumab Trial in Guangzhou (Durvalumab, etoposide, and cisplatin/carboplatin followed by

Recruiting
  • Lung Cancer
  • +2 more
  • Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 17, 2022

Bladder Cancer, High-Risk Cancer, Tremelimumab Trial in Vancouver (Tremelimumab)

Recruiting
  • Bladder Cancer
  • +4 more
  • Vancouver, British Columbia, Canada
    Vancouver General Hospital
Nov 3, 2021

Immunological, Molecular-genetic, Image-based and Microbial

Recruiting
  • Oncology
  • +4 more
  • Non-interventional
  • Munich, Bavaria, Germany
    LMU University Hospital
Aug 31, 2021

Leptomeningeal Metastasis, Durvalumab Trial (Durvalumab, methotrexate)

Not yet recruiting
  • Leptomeningeal Metastasis
  • Durvalumab
  • (no location specified)
May 22, 2020

Anlotinib, Durvalumab, Small Cell Lung Cancer Trial (Anlotinib In Combination With Durvalumab)

Unknown status
  • Anlotinib
  • +2 more
  • Anlotinib In Combination With Durvalumab
  • (no location specified)
Mar 17, 2020